Supplementary Figure 1 A B C siControl siRNF31 siRNF31+siP53 siControl G2-M: 23.2% G1:76.7% S: 7.5% G2-M: 15.9% G1:66.5% S: 15.6% G2-M: 18.3% B siControl siRNF31 siRNF31+siP53 C siControl siRNF31 siRNF31+siP53
Supplementary Figure 2 A B * Relative cell viability Cisplatin siControl siRNF31 siRNF31+siP53 Vehicle Cisplatin 3.5% 3.7% 12.5% 18.5% 11.5%
Supplementary Figure 3 Empty Vector P53 overexpression Sub-G1 phase(Percentage) 12.4±0.1 10.4±0.3
Supplementary Figure 4 A B Vehicle Nutlin-3 Relative mRNA expression *